Selpercatinib Cuts Recurrence Risk in Early RET+ NSCLC

In the first phase 3 trial of a RET inhibitor as adjuvant therapy, selpercatinib markedly improved event-free survival vs placebo in early-stage RET fusion-positive NSCLC.
Medscape Medical News

source https://www.medscape.com/viewarticle/selpercatinib-cuts-recurrence-risk-early-ret-non-small-cell-2026a1000i25?src=rss

Comments

Post a Comment

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

From 1977 to 2003, seven Joint National Committees (JNC), sponsored by the National Heart, Lung, and Blood Institute (NHLBI), produced consensus multi-specialty guidelines on the diagnosis and management of hypertension. In 2013, well into the development of JNC8, the NHLBI abruptly turned the process over to the American College of Cardiology/American Heart Association (ACC/AHA). The JNC8 committee independently published an evidence-based guideline in JAMA that raised the blood pressure treatment threshold in most older adults from 140/90 to 150/90 mm Hg. Concerned about conflicts of interest and other deviations from Institute of Medicine-recommended practices for developing trustworthy guidelines , primary care groups, including the American Academy of Family Physicians (AAFP), declined to participate in the ACC/AHA guideline panel. And the longstanding edifice of hypertension guidelines fractured. In 2017, the ACC/AHA released its clinical practice guideline , which most notab...
Read more